Business Wire

Christie’s Global Auction Channel Sales Total £3.9 Billion/US$5.0 Billion In 2019

21.12.2019 02:17:00 EET | Business Wire | Press release

Share

Christie’s announced auction channel sales of £3.9 billion (US$5 billion) for 2019.

Key highlights for the year included:

  • A new top price for any living artist at auction, achieved with Jeff Koon’s Rabbit, which realized US$91,075,000 at Christie’s New York in May 2019.
  • Numerous record prices in 2019, including top prices for artworks and objects sold in London (David Hockney, Henry Geldzahler and Christopher Scott, for £37,661,248/US$49,521,696), Hong Kong (Sanyu, Five Nudes, for HK$303,984,992/US$38,848,420) and Geneva (Patek Philippe Grandmaster Chime ref. 6300A for ONLY WATCH for CHF31,000,000/US$31,244,094). In Paris Nicolas de Staël’s Parc des Princes realized €20,000,000/US$22,254,368, and set a record for the artist and was the top price for any lot sold at Christie’s Paris this year.
  • Christie’s remained the auction house of choice for major private and estate collections, achieving the top three results for named collections in 2019 with Masterpieces from the Collection of S.I. Newhouse, The Robert B. and Beatrice C. Mayer Family Collection, and Maharajas and Mughal Magnificence.
  • Strong results were also achieved for the collections of notable collectors David Gilmour, Drue Heinz, the Irving Collection, James and Marilynn Alsdorf, Terry Allen Kramer, Eileen and I.M. Pei, Richard L. Weisman, George Michael, the Clarke Collection, Ron and Diane Disney Miller, the Matthys-Colle Collection, works from the UniCredit Group, Jeremy Lancaster, and masterpieces from a Rothschild Collection.

Guillaume Cerutti, Chief Executive Officer, commented: “Amid a challenging global environment, demand for art remains strong and is reflected in our 2019 results, especially for Modern and Contemporary art. In the last month alone, we were particularly pleased by the results achieved in New York for Christie’s 20th Century Art week, in Hong Kong for our Autumn sale series—despite a heightened political context—and in London during our Classic Week sales, including Old Masters. We are looking forward to continuing the momentum in 2020.”

For more on Christie’s top 2019 moments, please visit our online feature here.

Christie’s will publish full 2019 results, inclusive of private and e-commerce channel sales, in early 2020.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

PRESS:
Nicky Eaton
London | presslondon@christies.com
New York | communicationsamericas@christies.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Bregal Milestone Backs Nethive With Majority Growth Investment and JoyComm Acquisition22.10.2026 11:00:00 EEST | Press release

Bregal Milestone, a leading European software growth private equity firm, today announced a majority growth investment in Nethive S.p.A. (“Nethive” or the “Company”), a leading Italian cybersecurity services and software provider. Alongside its investment in Nethive, Bregal Milestone has also backed Nethive’s acquisition of IT security specialist Joy Comm S.r.l. (“JoyComm”). Founded in 2014 by Alessandro Bellato and Diego Rocco, Nethive has become a trusted cybersecurity partner to blue-chip enterprises, SMEs, and public-sector organizations across Italy. Its platform spans managed security services, professional services and technology resale, helping organizations protect critical infrastructure and networks, strengthen cyber resilience and reduce operational complexity. Nethive combines deep technical expertise with 24/7 monitoring, threat detection and response, risk and vulnerability management, infrastructure protection and specialist consultancy. The Company serves more than 250

EOS and VOP CZ Sign Memorandum of Understanding to Explore Cooperation on Czech Programmes22.10.2026 10:00:00 EEST | Press release

EOS Defence Systems (EOS) and VOP CZ have signed a Memorandum of Understanding (MoU) at Future Forces Forum in Prague to explore cooperation on wheeled armoured vehicle programmes for the Czech Army and other future defence projects in the Czech Republic and Europe where VOP CZ is involved. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261021408045/en/ EOS and VOP CZ sign a Memorandum of Understanding at Future Forces Forum in Prague. Left to right: Martin van de Voorde, Sales Director Europe, EOS; Vlastimil Navrátil, Managing Director, VOP CZ; Pavla Ungrová, Sales Director, VOP CZ; Rear Admiral Richard Caton, Australia’s Military Representative to NATO and the EU; Group Captain Michael Schleeman, Australia’s Defence Attaché; and Matej Pupák, Program Lead, VOP CZ. The agreement brings together EOS' expertise in advanced remote weapon systems (RWS) with VOP CZ's established capabilities in military vehicle integration, produ

Ferrer and Prilenia Announce Authorization for EU Initiation of Confirmatory PRECISE-HD Study of Pridopidine in Huntington's Disease22.10.2026 10:00:00 EEST | Press release

Ferreri and Prilenia Therapeutics B.V.today announced that the confirmatory Phase 3 PRECISE-HD study of investigational pridopidine in Huntington's disease (HD) has received authorization to begin in participating EU Member States (EU CT number: 2026-526093-16-00, NCT07609108). Recruitment in the EU is expected to commence this month, joining currently recruiting sites in the US and UK, with Canada to follow. Designed to evaluate the efficacy and safety of pridopidine (administered as an oral capsule twice a day), and to generate data for regulatory evaluation, the global, approximately 400-participant, randomized, double-blind, placebo-controlled PRECISE-HD study will assess the clinical effect of the investigational treatment on disease progression, functional capacity, motor function, cognition, speech and quality of life. “The initiation of PRECISE-HD in Europe marks a milestone for the Huntington’s disease research community. This confirmatory Phase 3 study has been designed to bu

IQM Quantum Computers Announces Conference Call to Report Third Quarter 2026 Financial Results on November 5, 202622.10.2026 09:00:00 EEST | Press release

As published previously, IQM Quantum Computers Plc (Nasdaq: IQMX) ("IQM" or the "Company"), a global leader in superconducting quantum computers, will report financial results for the third quarter 2026 on Thursday, November 5, 2026. CEO Dr. Jan Goetz and CFO Jan Kuerschner will host a conference call at 3:00 PM EET / 2:00 PM CET / 8:00 AM EST on the same day followed by a Q&A session with analysts. Conference Call and Webcast A live audio webcast of the conference call will be available to the public through the link below and can be accessed in the News & Events section of IQM's Investor Relations website at https://investors.iqm.tech/. A replay of the call will be available at the same location for one year following the call. Participation in the Q&A during the conference call will require registration using the link below. Date: Thursday, November 5, 2026 Time: 3:00 PM EET / 2:00 PM CET / 8:00 AM EST Webcast Link: https://edge.media-server.com/mmc/p/syqjnhp6To ask questions on the

Galderma Delivers Net Sales of 4.765 B USD in the First Nine Months, Up 25.1% at Constant Currency Year-on-Year, and Raises Full-Year Net Sales Guidance22.10.2026 08:00:00 EEST | Press release

Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced its sales performance for the first nine months of 2026. Record net sales of 4.765 billion USD for thefirst nine months of 2026, representing 25.1% year-on-year growth at constant currency1, predominantly driven by volume and complemented by favorable mix. Broad-based double-digit growth across geographies and product categories, reflecting strong execution of Galderma’s proven integrated dermatology strategy, with stand-out performance in Therapeutic Dermatology, across both Nemluvio and the mature portfolio, as well as in Dermatological Skincare and Neuromodulators. Continued market outperformance across all three product categories, with net sales growth year-on-year at constant currency of 13.2% in Injectable Aesthetics, 16.2% in Dermatological Skincare, and 64.4% in Therapeutic Dermatology (with Nemluvio net sales of 735 million USD). Strengthening Galderma’s dermatology platform, with the pre

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye